A sensitive immunochemical assay for measuring the concentration of the activated protein C-protein C inhibitor complex in plasma: Use of a catcher antibody specific for the complexed/cleaved form of the inhibitor

Thrombosis and Haemostasis

Volumn 86, Issue 2, 2001, Pages 604-610

  Strandberg, K ^a   Kjellberg, M ^a   Knebel, R ^a   Lilja, H ^a   Stenflo, J ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; APROTININ; BENZAMIDINE; MONOCLONAL ANTIBODY; PROTEIN C; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SOYBEAN TRYPSIN INHIBITOR;

ANTIBODY AFFINITY; ARTICLE; ASSAY; BLOOD LEVEL; DEEP VEIN THROMBOSIS; DRUG ANTAGONISM; DRUG INHIBITION; HUMAN; HYPERCOAGULABILITY; IMMUNOCHEMISTRY; IMMUNOFLUORESCENCE; LINEAR SYSTEM; MEASUREMENT; PRIORITY JOURNAL;

EID: 0034909689     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616093     Document Type: Article

References (37)

1. The protein C anticoagulant system
2. Endothelial protein C receptor
3. The refined 1.9-Å X-ray structure of D-Phe-Pro-Arg chloromethylketone-inhibited human α-thrombin: Structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships
4. What do dysfunctional serpins tell us about molecular mobility and disease?
5. Protein C inhibitor. Purification from human plasma and characterization
6. Activated protein C inhibitor
7. Physiological inhibition of human activated protein C by α-1-antitrypsin
8. Heparin binding to protein C inhibitor
9. Hemostatic abnormalities in patients with pulmonary embolism compared with that in deep vein thrombosis
10. Decreased protein C inhibitor after percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction
11. Increased activated protein C-protein C inhibitor complex levels in patients with pulmonary embolism
12. Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease
13. Increased activated protein C: Protein C inhibitor complex and decreased protein C inhibitor levels in patients with chronic renal failure on maintenance hemodialysis
14. Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 Å and full insertion of the reactive center loop into β-sheet A
15. Structure of a serpin-protease complex shows inhibition by deformation
16. Characterization of a cDNA for human protein C inhibitor: A new member of the plasma serine protease inhibitor superfamily
17. Protein C inhibitor from human plasma: Characterization of native and cleaved inhibitor and demonstration of inhibitor complexes with plasma kallikrein
18. Topology of the stable serpin-protease complex revealed by an autoantibody that fails to react with the monomeric conformers of antithrombin
19. Identification of an epitope in antithrombin appearing on insertion of the reactive-bond loop into the A β-sheet
20. Expression of functional human C1 inhibitor in COS cells
21. Immunologic evidence for insertion of the reactive-bond loop of antithrombin into the A β-sheet of the inhibitor during trapping of target proteinases
22. Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serine proteinases
23. In vivo and in vitro complexes of activated protein C with twp inhibitors in baboons
24. Turnover of *I-protein C inhibitor and *I-α 1-antitrypsin and their complexes with activated protein C
25. Determination of functional and antigenic protein C inhibitor and its complexes with activated protein C in plasma by ELISA's
26. Activated protein C-protein C inhibitor complex formation: Characterization of a neoepitope provides evidence for extensive insertion of the reactive center loop
27. 2+ binding and biological activity
28. Vitamin K and the biosynthesis of prothrombin V. γ-carboxyglutamic acids, the vitamin K-dependent structures in prothrombin
29. Europium as a label in time-resolved immunofluorometric assays
30. Human plasma protein C. Isolation, characterization and mechanism of activation by α-thrombin
31. Mechanisms of hypercoagulability
32. Circulating tissue thromboplastin during hip surgery
33. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo
34. Late occurring clinical deep vein thrombosis in joint-operated patients
35. Activation of the protein C pathway in acute sepsis